-
1.发明授权The use of activated t-lymphocytes for preparing a pharmaceutical composition for the treatment of AIDS 失效用于制备用于治疗AIDS的药物组合物使用活化的T淋巴细胞的。
公开(公告)号：EP0260714B1
公开(公告)日：1994-06-29
申请号：EP87113709.7
申请日：1987-09-18
CPC分类号： A61K39/21 , A61K39/12 , A61K2039/5158 , C12N2740/16034
摘要： The invention relates to the use of activated T lymphocytes at a dosage effective in transferring cell mediated imunity against AIDS virus infected cells in vivo, in which: (a) the activated T lymphocytes are specific for an epitope of the AIDS virus and histocompatible with the patient; and (b) the activated T lymphocytes are capable of mediating AIDS virus specific T cell immunity as measured by either of the following assays: (i) a cytotoxicity assay in which the activated T lymphocytes are incubated with the patient's radiolabelled target cells infected with AIDS virus, the release of radiolabel being an indication of lysis of the infected target cells; and (ii) a stimulation assay which measures the ability of the activated T lymphocytes to proliferate and/or produce a lymphokine in response to stimulation with an epitope of the AIDS virus in vitro for preparing a pharmaceutical composition for the treatment of AIDS.
-
2.发明公开The use of activated t-lymphocytes for preparing a pharmaceutical composition for the treatment of AIDS 失效用于制备用于治疗AIDS的药物组合物使用活化的T淋巴细胞的。
公开(公告)号：EP0260714A2
公开(公告)日：1988-03-23
申请号：EP87113709.7
申请日：1987-09-18
CPC分类号： A61K39/21 , A61K39/12 , A61K2039/5158 , C12N2740/16034
摘要： The invention relates to the use of activated T lymphocytes at a dosage effective in transferring cell mediated imunity against AIDS virus infected cells in vivo, in which:
(a) the activated T lymphocytes are specific for an epitope of the AIDS virus and histocompatible with the patient; and
(b) the activated T lymphocytes are capable of mediating AIDS virus specific T cell immunity as measured by either of the following assays:
(i) a cytotoxicity assay in which the activated T lymphocytes are incubated with the patient's radiolabelled target cells infected with AIDS virus, the release of radiolabel being an indication of lysis of the infected target cells; and
(ii) a stimulation assay which measures the ability of the activated T lymphocytes to proliferate and/or produce a lymphokine in response to stimulation with an epitope of the AIDS virus in vitro
for preparing a pharmaceutical composition for the treatment of AIDS.摘要翻译： 本发明涉及在有效地抵抗在体内AIDS病毒感染的细胞传递环细胞介导的imunity的剂量使用活化的T淋巴细胞，其中：（a）所述活化的T淋巴细胞特异于在爱滋病病毒的表位和组织相容性与 病人; 和（b）的活化的T淋巴细胞能够介导艾滋病病毒特异性T细胞免疫为通过以下测定来测量的：（ⅰ）的细胞毒性测定法，其中所述活化的T淋巴细胞与感染了艾滋病患者的放射性标记的靶细胞温育 病毒，放射性标记物是被感染的靶细胞的裂解的指示的释放; 和（ii）刺激测定法，其测量该活化的T淋巴细胞的增殖和/或响应于刺激在体外爱滋病病毒的表位在制备用于治疗AIDS的药物组合物产生淋巴因子的能力。
-
搜索结果
2 条记录 (耗时 0.009 秒)
